Company news
Cabio Biotech (wuhan) Co. Ltd. Class A (SSE:688089) news
Cabio Biotech (wuhan) Co. Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: (688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Progress…
Press releases & updates
(688089)"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Progress of the Imposition of Other Risk Warning on the Company's Shares
September 29, 2026
"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Receipt of the Notice of Response to Retrial and Progress of Litigation
September 14, 2026
"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Progress of the Imposition of Other Risk Warning on the Company's Shares
August 28, 2026
"Cabio Biotech (Wuhan) Co., Ltd."Semi-annual Report for 2026
August 21, 2026
"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Resignation of Independent Director
August 12, 2026
"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Implementation of Cancellation of Repurchased Shares and Share Changes
August 3, 2026
"Cabio Biotech (Wuhan) Co., Ltd."Announcement on Imposition of Other Risk Warnings and Trading Suspension
July 24, 2026
Announcement on Notifying Creditors Regarding the Cancellation of Repurchased Shares
June 17, 2026
Announcement on Resolutions of the 2025 Annual General Meeting
June 15, 2026
Announcement on Voluntary Disclosure of the Approval of Lacto-N-neotetraose
June 8, 2026
Notice on Convening the 2025 Annual General Meeting
May 24, 2026
Announcement on Participating in the SSE STAR Market's 2025 Annual Biological Products Industry Collective Performance Briefing and the Q1 2026 Performance Briefing
May 5, 2026
Special Report on Deposit and Actual Use of Raised Funds in 2025
April 22, 2026
Announcement on Resignation of Directors
March 25, 2026
Announcement on Preliminary Earnings Estimate for 2025
February 27, 2026
Announcement on Implementation Result of Phase II Shares Repurchase and Share Changes
January 26, 2026
Announcement on Progress in Repurchasing Shares through Call Auction in Phase II
January 5, 2026
Announcement on Closing Some Investment Projects Financed by Raised Funds, Using Residual Raised Funds to Permanently Supplement Current Capital, and Cancellation of Related Special Account for Raised Funds
December 25, 2025
Announcement on Convening the Q3 2025 Performance Briefing
December 5, 2025
CABIO Showcases Life-Stage Nutrition Innovation at Fi Europe 2025 Paris as the New Global Headquarter Opens
December 3, 2025
嘉必优生物技术（武汉）股份有限公司2025年第二次临时股东大会决议公告
November 18, 2025
Announcement on Litigation Progress and Final Judgment Victory
November 3, 2025
Announcement on Canceling the Board of Supervisors, Changing Registered Address, Amending the "Articles of Association", and Formulating and Revising Some Governance Systems
October 27, 2025
Announcement on Voluntary Disclosure of Expected Increase in Performance for the First Three Quarters of 2025
October 15, 2025
Announcement on Self-Inspection Report on Trading Situation of Relevant Entities in Stock Market Concerning Termination of Issuing Shares and Paying Cash for Asset Acquisition, Raising Matching Funds, and Related Party Transaction
September 22, 2025
Announcement on Initially Repurchasing the Company's Shares through Phase II Call Auction
September 9, 2025
Announcement on Resolutions of the 9th Meeting of the 4th Board of Directors
September 8, 2025
Announcement on Attending Semi-annual Collective Performance Briefing for Enterprises in Biological Products and CXO Industries on SSE STAR Market 2025
September 5, 2025
Announcement on Cancellation of Some Special Accounts for Raised Funds
September 2, 2025
Announcement on Holding the Investors' Briefing on Terminating Major Asset Restructuring
August 29, 2025
Announcement on Resolutions of the 7th Meeting of the 4th Board of Supervisors
August 18, 2025
Announcement on the Halfway Point of the 2nd Share Repurchase Period Without Any Repurchase Implemented
July 24, 2025
Announcement on Voluntary Disclosure of Earnings Pre-increase for 2025 Interim Results
July 18, 2025
Announcement on Plan of Shareholding Reduction by Shareholder
July 6, 2025
Announcement on Adjusting the Upper Limit of Phase II Share Repurchase Price after Implementation of Dividend Distribution for 2024
July 2, 2025
Announcement on Reply to the Review Inquiry Letter of Application for Purchasing Assets and Raising Supporting Funds by Issuing Shares and Paying Cash as well as Related Party Transactions
June 10, 2025
Announcement on Convening the Q1 2025 Performance Briefing
June 6, 2025
Announcement on Resolution of the 2024 Annual General Meeting
May 29, 2025
Announcement on Changing Major Asset Restructuring Project and Audit Signatory Accountant for 2025
May 16, 2025
Notice on Convening the 2024 Annual General Meeting
May 8, 2025
Announcement on Adjusting 2024 Annual Profit Distribution Plan
April 28, 2025
Announcement on Attending 2024 SSE STAR Market Biological Products and CXO Industry Collective Performance Briefing
April 14, 2025
Announcement on Changing Enterprise Type
March 27, 2025
Announcement on Self-Inspection Report on Purchase and Sale of Shares by Relevant Subjects Related to This Transaction
March 20, 2025
Indicative Announcement on Risk of Purchase of Assets and Raising of Supporting Funds through Shares Issuance and Cash Payment and Related Transaction
March 4, 2025
Announcement on Preliminary Earnings Estimate for 2024
February 27, 2025
Announcement on Adjustment of Core Technical Personnel
February 24, 2025
Announcement on Progress in Planning Major Asset Restructuring
February 10, 2025